CBFA2T3 was initially identified as a fusion partner with RUNX1 in therapy-related AML and shown to facilitate transcriptional repression, as well as being implicated in hematopoietic stem cell quiescence [29]. The gene discussed is CBFA2T3; the disease is acute myeloid leukemia.